Targeting cardiac natriuretic peptides in the therapy of diabetes and obesity.
Expert Opin Ther Targets
; 20(12): 1445-1452, 2016 Dec.
Article
en En
| MEDLINE
| ID: mdl-27786597
ABSTRACT
INTRODUCTION:
Atrial and B-type Natriuretic Peptides (NP) are cardiac hormones with potent cardiovascular and metabolic effects. They signal through the NPRA/cGMP system and are inactivated by a clearance receptor NPRC and neutral endopeptidases (NEP). Recombinant ANP and BNP are currently used as drug treatment for acute decompensated congestive heart failure. Recent literature indicate that a defective NP system is linked to obesity and predict the risk of type 2 diabetes (T2D). Areas covered This article reviews recent epidemiological, clinical and preclinical evidences that NP system deficiency may be causal of obesity and T2D. The molecular mechanisms of the NP pathway in several metabolic target tissues are presented. The therapeutic potential of NP in obesity and T2D is discussed. Expert opinion Targeting the NP pathway may offer a novel therapeutic avenue for the management of obesity and T2D. The benefit/risk of drugs increasing circulating NP levels by blocking NPRC and NEP, and/or enhancing NPRA signaling should be assessed in obese and type 2 diabetic individuals.Palabras clave
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Factor Natriurético Atrial
/
Péptido Natriurético Encefálico
/
Diabetes Mellitus Tipo 2
/
Obesidad
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Opin Ther Targets
Asunto de la revista:
TERAPEUTICA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Francia